Nivolumab + ipilimumab

CheckMate 214



livolumab + ipilimumab CheckMate 214				Nivolumab ·
PRELIMIN	NARY SCOR	lΕ		
CURATIVE				CURATIVE
				Overall Surv
NON-CURATIVE		Os		NON-CUR
ADJU:	STMENTS			Overall Surv
Quality of life				
ę _o		D -)	oʻ- No <i>l</i> i	Progression
				Non-inferior
Serious and disabling adverse effects				
(1.1)			<u></u>	Overall Res
Other adjustments				Overall Surv
Other adjustments			\bigcirc	INFORMA Tumour typ Therapeuti risk advand Experimen Control Arr



